HomeIndustriesBanks & FinanceCytokinetics (CYTK) CEO On Future Of Heart Disease Treatment

Cytokinetics (CYTK) CEO On Future Of Heart Disease Treatment

Cytokinetics (CYTK) CEO Robert Blum joins Nicole Petallides to give an overview of the company and discusses its Aficamten trial. He talks about how the Sequoia-HCM Phase 3 clinical trial showed the best-case scenario result for obstructive hypertrophic cardiomyopathy. He goes over the future of heart disease treatment. Cytokinetics is a biopharma company with a focus on muscle activators and inhibitors as potential disease treatments. Tune in to find out more about the stock market today.

Trading 360

03 Jan 2024

SHARE

ON AIR
education
2:30 am
Your First Trade
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
ON AIR
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Liz Ann Live
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Liz Ann Live
REPLAY
10:30 pm
The Wrap
REPLAY

Schwab Network's Newsletters

Daily insights for every investor